Frenelle Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Frenelle Pharma is a private, platform-based biotech company developing and commercializing its Faros™ long-acting injectable drug delivery technology. The company operates a unique business model of creating focused subsidiary ventures—SpineThera (Phase 2 for sciatica), Frenelle PBC (substance use disorders), and Anumio (animal health)—to advance programs from discovery to commercialization. With over a decade of R&D investment, proven preclinical data, and an active Phase 2 asset, Frenelle is positioned to disrupt markets in pain management, addiction, and veterinary medicine through improved therapeutic delivery.

Pain ManagementSubstance Use DisordersAnimal Health

Technology Platform

Faros™, a proprietary long-acting injectable (LAI) drug delivery platform proven in animal models and a Phase 2 study, with exploration into other delivery routes like inhalation.

Opportunities

The Faros™ platform addresses large markets with high unmet need: chronic pain (esp.

sciatica), the opioid epidemic via improved addiction treatments, and the high-growth pet care market.

The subsidiary model allows for targeted investment and partnerships, potentially accelerating multiple paths to value creation and revenue.

Risk Factors

Key risks include clinical failure of the lead Phase 2 asset (SX600), the complexity and resource intensity of managing three simultaneous subsidiary ventures, and competition in the crowded long-acting injectable delivery space.

Regulatory hurdles for novel delivery systems and dependency on key partners like the Mayo Clinic also pose significant challenges.

Competitive Landscape

Frenelle competes in the long-acting injectable drug delivery space against established platform companies (e.g., Alkermes, MedinCell) and large pharma with internal capabilities. In sciatica, it faces competition from steroids, NSAIDs, and novel neuromodulators. In substance use disorders, it competes with existing LAIs like Sublocade (buprenorphine) and Vivitrol (naltrexone). Differentiation will rely on Faros™'s specific performance profile and successful clinical outcomes.

More companies in Drug Delivery & Formulation →More companies in United States →